Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL408821 | 0.99 | TBXAS1 (0.60) | TBXAS1CYP2A6CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8803483 | 0.92 | TBXAS1 (0.60) | TBXAS1CYP2A6CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11237835 | 0.87 | TBXAS1 (0.58) | TBXAS1CYP2A6CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10247382 | 0.87 | CYP11B1 (0.58) | TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL10247518 | 0.87 | CYP19A1 (0.59) | TBXAS1CYP19A1 | |
| SCHEMBL8804091 | 0.86 | CYP19A1 (0.56) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8803778 | 0.86 | TBXAS1 (0.56) | TBXAS1 | |
| SCHEMBL8802725 | 0.86 | WDR5 (0.49) | TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL410653 | 0.86 | CYP19A1 (0.58) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11269558 | 0.86 | PLA2G4A (0.58) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688096-B2 | Methods for treatment of sleep-related breathing disorders | THE UNIVERSITY OF CHICAGO (US) | 2020-06-23 | — | — | US | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| WO-2013155218-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2013-10-17 | — | — | WO | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| EP-0649423-A1 | PROCESS FOR PREPARING 1,3-DIOXOLANE DERIVATIVES. | SYNTEX INC (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5274108-A | Process for preparing 1,3-dioxolane derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| WO-1993025549-A1 | PROCESS FOR PREPARING 1,3-DIOXOLANE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-12-23 | — | — | WO | disclosed |
| US-5208331-A | Process for preparing 1,3-dioxolane derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-05-04 | — | — | US | disclosed |
| US-5158949-A | 1,3-DIOXOLANE DERIVATIVES AS CHOLESTEROL-LOWERING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0492474-A1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4375474-A | BACTERICIDES, FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4359475-A | SPERMICIDES, MICROBIOCIDES OR ANTICONVULSANTS | SYNTEX (U.S.A.) INC. (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0049565-A2 | Derivatives of substituted N-alkylimidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4321272-A | Derivatives of substituted N-alkylimidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688096-B2 | Methods for treatment of sleep-related breathing disorders | HCRTR2, HCRTR1, CHRNB3 | TBXAS1 2654/4885CYP2A6 3384/4885CYP19A1 3800/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1071/4885CYP2A6 863/4885CYP19A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.